ReviewMicrobial cell factories2023
Increasing the production of the bioactive compounds in medicinal mushrooms: an omics perspective.
Review in Microbial cell factories, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 50 citations in OpenAlex.
- Application of Metabolomics in the Exploration of Bioactive Compounds and Drug Development from Medicinal Fungi.Metabolites · 2026Review
- Blue-Light Exposure Enhances Productivity, Total Phenolic Content, and Sensory Attributes in Edible Mushrooms: A Multispecies Study.Plant foods for human nutrition (Dordrecht, Netherlands) · 2026Article
- Mycogenic Nanomaterials: What Fungal Nanoparticles Promise and What Still Holds Them Back.Journal of fungi (Basel, Switzerland) · 2026Review
- Fungal-fungal interaction between Sanghuangporus vaninii and its endophytic Fusarium solani rewires host secondary metabolism to boost bioactive metabolite production.Microbial cell factories · 2026Article
- A Water Extract of Mixed Mushroom Mycelia Mitigates Cognitive Deficit and Oxidative Stress After Global Cerebral Ischemia-Reperfusion Injury.Current issues in molecular biology · 2026Article
- Mycelium as a natural food fortificant: production, micronutrient enrichment, processing, and application in functional foods.Frontiers in nutrition · 2026Review
- Combined Transcriptomic and Metabolomic Analyses of the Response ofJournal of fungi (Basel, Switzerland) · 2025Article
- Green-Synthesized Nanomaterials from Edible and Medicinal Mushrooms: A Sustainable Strategy Against Antimicrobial Resistance.Pharmaceutics · 2025Review
- Regulation and induction of fungal secondary metabolites: a comprehensive review.Archives of microbiology · 2025Review
- A Review of Genomic, Transcriptomic, and Proteomic Applications in Edible Fungi Biology: Current Status and Future Directions.Journal of fungi (Basel, Switzerland) · 2025Review
- Lion's Mane Mushroom (Nutrients · 2025Review
- Decoding the Tissue-Specific Profiles of Bioactive Compounds inJournal of fungi (Basel, Switzerland) · 2025Article
- Where Biology Meets Engineering: Scaling Up Microbial Nutraceuticals to Bridge Nutrition, Therapeutics, and Global Impact.Microorganisms · 2025Review
- Mushroom against Cancer: Aqueous Extract ofNutrients · 2024Article
- The Effect of Green Extraction Technologies on the Chemical Composition of Medicinal Chaga Mushroom Extracts.Journal of fungi (Basel, Switzerland) · 2024Article
- Biotechnological Applications of Mushrooms under the Water-Energy-Food Nexus: Crucial Aspects and Prospects from Farm to Pharmacy.Foods (Basel, Switzerland) · 2023Review
- Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macroscopic fungi, mainly higher basidiomycetes and some ascomycetes, are considered medicinal mushrooms and have long been used in different areas due to their pharmaceutically/nutritionally valuable bioactive compounds. However, the low production of these bioactive metabolites considerably limits the utilization of medicinal mushrooms both in commerce and clinical trials. As a result, many attempts, ranging from conventional methods to novel approaches, have been made to improve their production. The novel strategies include conducting omics investigations, constructing genome-scale metabolic models, and metabolic engineering. So far, genomics and the combined use of different omics studies are the most utilized omics analyses in medicinal mushroom research (both with 31% contribution), while metabolomics (with 4% contribution) is the least. This article is the first attempt for reviewing omics investigations in medicinal mushrooms with the ultimate aim of bioactive compound overproduction. In this regard, the role of these studies and systems biology in elucidating biosynthetic pathways of bioactive compounds and their contribution to metabolic engineering will be highlighted. Also, limitations of omics investigations and strategies for overcoming them will be provided in order to facilitate the overproduction of valuable bioactive metabolites in these valuable organisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.